Management of Tardive Syndrome: Medications and Surgical Treatments

• Type of Material: Article
• Authors: Stewart Factor, Emory University
• Language: English
• Date: 2020-07-27
• Publisher: SPRINGER
• Publication Version: Final Published Version
• Copyright Statement: © The American Society for Experimental NeuroTherapeutics, Inc. 2020
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1007/s13311-020-00898-3
• Title of Journal or Parent Work: NEUROTHERAPEUTICS
• Volume: 17
• Issue: 4
• Start Page: 1694
• End Page: 1712
• Grant/Funding Information: The study received funding from Sartain Lanier Family Foundation.
• Keywords: Clinical Neurology; therapy; AMANTADINE HYDROCHLORIDE; HUNTINGTON-DISEASE; BOTULINUM TOXIN; Science & Technology; SCHIZOPHRENIC-PATIENTS; PROPRANOLOL THERAPY; VMAT2 inhibitors; botulinum toxin; DOUBLE-BLIND; Pharmacology & Pharmacy; Tardive syndrome; 2ND-GENERATION ANTIPSYCHOTICS; Life Sciences & Biomedicine; DEEP BRAIN-STIMULATION; Neurosciences; Neurosciences & Neurology; deep brain stimulation; GLOBUS-PALLIDUS; MOVEMENT-DISORDERS
• Research Categories: Health Sciences, Medicine and Surgery

Abstract

Tardive syndrome (TS) is an iatrogenic, often persistent movement disorder caused by drugs that block dopamine receptors. It has a broad phenotype including movement (orobuccolingual stereotypy, dystonia, tics, and others) and nonmotor features (akathisia and pain). TS has garnered increased attention of late because of the Food and Drug Administration approval of the first therapeutic agents developed specifically for this purpose. This paper will begin with a discussion on pathogenesis, clinical features, and epidemiology. However, the main focus will be treatment options currently available for TS including a suggested algorithm based on current evidence. Recently, there have been significant advances in TS therapy, particularly with the development of 2 new vesicular monoamine transporter type 2 inhibitors for TS and with new data on the efficacy of deep brain stimulation. The discussion will start with switching antipsychotics and the use of clozapine monotherapy which, despite the lack of higher-level evidence, should be considered for the treatment of psychosis and TS. Anti-dyskinetic drugs are separated into 3 tiers: 1) vesicular monoamine transporter type 2 inhibitors, which have level A evidence, are approved for use in TS and are recommended first-choice agents; 2) drugs with lower level of evidence for efficacy including clonazepam, Ginkgo biloba, and amantadine; and 3) drugs that have the potential to be beneficial, but currently have insufficient evidence including levetiracetam, piracetam, vitamin B6, melatonin, baclofen, propranolol, zolpidem, and zonisamide. Finally, the roles of botulinum toxin and surgical therapy will be examined. Current therapies, though improved, are symptomatic. Next steps should focus on the prevention and reversal of the pathogenic process.